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Abstract: Type 2 diabetes mellitus (T2DM) has insulin resistance (IR) or reduced ฀-cell mass, partially
due to an increased ฀-cell apoptosis rate. Pancreatic stone protein/regenerating protein (PSP/reg) is
a secretory protein produced in the pancreas and up-regulated dramatically during pancreatic disease.
Recent studies revealed that ฀-cells undergoing apoptosis induce PSP/reg expression in surviving neigh-
boring cells. Further experiments demonstrated that PSP/reg was elevated during disease progression
in type 1 diabetes mellitus (T1DM). However, the association between PSP/reg and T2DM patients is
unknown. The aim of this pilot study was to investigate PSP/reg in different clinical stages of T2DM
and evaluate its correlation with chronic complications of diabetes. A total of 1,121 participants (479
males, 642 females; age range 23-80 years) were enrolled in this study. PSP/reg serum values were mea-
sured by a newly developed enzyme-linked immunosorbent assay (ELISA). We analyzed its correlation
with clinical and biochemical parameters in subjects with T2DM at different clinical phases. Statistical
analyses were conducted using SPSS 17.0 software. Correlations of PSP/reg and clinical parameters were
performed using Spearman’s rank correlation coefficient. Differences between groups were determined by
Nemenyi test. PSP/reg was elevated in high-risk and impaired glucose regulation (IGR) patients (p <
0.05). PSP/reg was significantly up-regulated in newly diagnosed T2DM patients and long-term diabetes
patients with complications (p < 0.001). PSP/reg levels correlated with the duration of diabetes (p <
0.001). The area under the curve (AUC) for presence of diabetes-onset and its chronic complications
was 0.640 and 0.754, respectively. PSP/reg is significantly up-regulated in T2DM patients, and PSP/reg
levels are related to the duration of diabetes. Therefore, PSP/reg might be useful as a predictor of T2DM
and disease progression.
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Abstract Type 2 diabetes mellitus (T2DM) has insulin
resistance (IR) or reduced b-cell mass, partially due to an
increased b-cell apoptosis rate. Pancreatic stone protein/
regenerating protein (PSP/reg) is a secretory protein pro-
duced in the pancreas and up-regulated dramatically during
pancreatic disease. Recent studies revealed that b-cells
undergoing apoptosis induce PSP/reg expression in surviv-
ing neighboring cells. Further experiments demonstrated
that PSP/reg was elevated during disease progression in type
1 diabetes mellitus (T1DM). However, the association
between PSP/reg andT2DMpatients is unknown. The aim of
this pilot study was to investigate PSP/reg in different clin-
ical stages of T2DMand evaluate its correlationwith chronic
complications of diabetes. A total of 1,121 participants (479
males, 642 females; age range 23–80 years) were enrolled in
this study. PSP/reg serum values were measured by a newly
developed enzyme-linked immunosorbent assay (ELISA).
We analyzed its correlation with clinical and biochemical
parameters in subjects with T2DM at different clinical
phases. Statistical analyses were conducted using SPSS 17.0
software. Correlations of PSP/reg and clinical parameters
were performed using Spearman’s rank correlation coeffi-
cient. Differences between groups were determined by
Nemenyi test. PSP/reg was elevated in high-risk and
impaired glucose regulation (IGR) patients (p\ 0.05). PSP/
reg was significantly up-regulated in newly diagnosed
T2DM patients and long-term diabetes patients with com-
plications (p\ 0.001). PSP/reg levels correlated with the
duration of diabetes (p\ 0.001). The area under the curve
(AUC) for presence of diabetes-onset and its chronic com-
plications was 0.640 and 0.754, respectively. PSP/reg is
significantly up-regulated in T2DM patients, and PSP/reg
levels are related to the duration of diabetes. Therefore, PSP/
reg might be useful as a predictor of T2DM and disease
progression.
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Introduction
Type 2 diabetes mellitus (T2DM) is an epidemic global
health hazard with estimated 113.9 million adults in China
and rapidly-rising incidence rates [1, 2]. This detrimental
disease affects health, life expectancy, quality of life, and is
a heavy burden to the health care systems for its continuing
medical care requirements and self-management education
[3]. It is also a leading cause of morbidity and disability,
which results in macrovascular and microvascular com-
plications [4]. Frequently, T2DM is only diagnosed when
complications occur. The latest study of prediabetes among
Chinese adults was more than 50 % [2]. The increasing
prevalence, serious complications, and high-undiagnosed
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rate make T2DM an important field of research. Two major
defects play a crucial role in disease progression of T2DM:
insulin resistance (IR) and b-cell failure or eventual loss of
b-cell mass [5]. Approximately, 80 % of the IR patients are
able to compensate, at least for a period of time, due to the
b-cell capability of compensating with hyperinsulinemia to
overcome IR [6].
Pancreatic stone protein/regenerating protein (PSP/reg)
was originally identified in pancreatic stones, as a 16 kDa
polypeptide belonging to the superfamily of calcium-
dependent lectin gene [7]. PSP/reg and its related homolog
pancreatitis associated protein/regIII share highly con-
served amino acid sequences. They contain sensitive
N-terminal trypsin cleavage sites, as well as conserved
functional responses in conditions of pancreatic stress.
Activated PSP/reg polymerizes into highly organized
fibrillar structures with helical configurations [8]. It has
been studied mainly in the pancreas and is prominently up-
regulated in acute or chronic pancreatitis [9]. In addition,
the same protein has been associated with islet regenera-
tion. PSP/reg appeared to boost b-cell growth and regen-
eration by induction of cellular proliferation [7, 10]. PSP/
reg was also found to be altered in the condition of sepsis
[11], ventilator associated pneumonia (VAP) [12], chronic
obstructive pulmonary disease (COPD) exacerbation [13],
and posttraumatic complications [14] which indicated that
PSP/reg might serve as a reflection of infectious conditions
and organ failure. Recently, PSP/reg has been suggested to
be associated with diabetes. A study by Bonner et al.
reported that b-cell apoptosis might stimulate the PSP/reg
expression in surviving neighboring cells, which could
facilitate the recovery of b-cell mass [15]. Moreover, ele-
vated PSP/reg level was observed in both of the disease
progression state of HNF1A–maturity onset diabetes of the
young (HNF1A-MODY) and the type 1 diabetes mellitus
(T1DM) human subjects [16]. However, the association of
PSP/reg and T2DM has not been reported.
In this study, we investigate whether serum PSP/reg is
associated with the presence of T2DM and its chronic
complications in patients at different phases of diabetes,
and to assess its predictive value of disease progression.
Materials and methods
Setting and study population
A total of 1121 participants (479 males, 642 females; age
range 23–80 years) were enrolled in this study. Data and
serum samples were collected within a multi-center trial.
The subjects were divided into five groups, including
patients with high-risk for diabetes (n = 254), clinically
diagnosed impaired glucose regulation (IGR) patients
(n = 342), newly diagnosed T2DM (n = 213), long-term
T2DM (without complications: n = 116, with complica-
tions: n = 79), and 117 volunteers were also enrolled as a
healthy control group in the study. The study was carried
out at eight community hospitals in Nanjing, Jiangsu,
China (Hongshan, Xuanwu, Tongrenjie, Mochou, Fuzi-
miao, Shuangtang, Zhonghuamen, and Xujiaxiang) and
Zhongda Hospital, Southeast University, Nanjing from
September 2010 to February 2012. PSP/reg was analyzed,
retrospectively. The study was performed according to the
principles of the Declaration of Helsinki and was approved
by the institutional clinical research ethics committee in
China. All subjects provided informed consent to partici-
pate in the study.
Diagnostic criteria
The diagnostic criteria for diabetes were according to the
American Diabetes Association (ADA) criteria 2012 [17].
Impaired glucose regulation (IGR) was defined as having
impaired fasting glucose (IFG) (the fasting plasma glucose
[FPG] levels 5.6 mmol/L to 6.9 mmol/L), or impaired
glucose tolerance (IGT) (2-h values in the OGTT of
7.8 mmol/L to 11.0 mmol/L) without a previous diabetes
diagnosis.
High-risk group of T2DM was defined as : (1)
HbA1c[= 5.7 %, IGT, or IFG on previous testing; (2)
Adults who are overweight (BMI[=25 kg/m2) and who
have one or more additional risk factors: a. physical inac-
tivity; b. first-degree relative with diabetes; c. women who
delivered a baby weighing[ 4,000 g or who were diag-
nosed with gestational diabetes mellitus (GDM), any
degree of glucose intolerance with onset or first recognition
during pregnancy; d. hypertension (blood pressure[=140/
90 mmHg or on therapy for hypertension); e. HDL cho-
lesterol level\35 mg/dl (0.90 mmol/L) and/or a triglyc-
eride level [250 mg/dl (2.82 mmol/L); f. women with
polycystic ovary syndrome (PCOS), a common hormonal
disorder among women of reproductive age; g. other
clinical conditions associated with insulin resistance; h.
history of cardiovascular disease [3].
Chronic complications of diabetes were assessed: all
patients with diagnosis diabetes were checked for chronic
complications. (1) Macroangiopathy: Coronary heart dis-
ease was diagnosed by clinical or electrocardiographic
criteria, or by positive ischemic stress tests. Patients with
suggestive symptoms of cerebrovascular disease (dizziness,
nausea, or vomiting; unusually severe headache; confusion,
disorientation, or memory loss; numbness, weakness in an
arm, leg, or the face, especially on one side; abnormal or
slurred speech; difficulty with comprehension; loss of
vision or difficulty seeing; loss of balance, coordination, or
the ability to walk) were evaluated with a central nervous
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system (CNS) computerized tomography. (2) Nephropathy:
It requires at least two urinary albumin excretion ratios
(UAE)[=30 mg/24 h or proteinuria[= 0.5 g/24 h, or
confirmed reduction of the glomerular filtration rate (cre-
atinine clearance\1 mL/s or serum creatinine[130 umol/
L). (3) Retinopathy: A fundus eye examination was applied
to evaluate and diagnose diabetic retinopathy. (4) Neu-
ropathy: It was defined by an abnormal neurologic exam-
ination consistent with the presence of peripheral
sensorimotor neuropathy. Clinical examination for diabetic
neuropathy included inspection of the feet and evaluation
of reflexes and sensory responses to vibration, light touch,
and pinprick. In addition, some patients also underwent
some special examination, such as magnetic resonance
imaging (MRI) and electromyography [18].
Exclusion criteria were (1) enrolled in another trial; (2)
T1DM; (3) unstable angina (unexpected chest pain and
usually occurs while resting); (4) blood pressure[=200/
100 mmHg; (5) active infection; (6) with active tumor and
take radiotherapy or chemotherapy within 6 months; (7) on
medicine affecting blood or urine glucose levels (hormone,
anti-hypertensive drugs, antibiotics, or NSAID).
Baseline assessment
A full clinical assessment was taken at the time of enroll-
ment, including medical history and physical examination.
Anthropometric measurements including height, weight,
waistline, hipline, body mass index (BMI), and waist hip
rate (WHR) were obtained. Personal information such as
age, gender, smoking, drinking, family history of diabetes,
and duration of diabetes was also recorded. All subjects
underwent a 75 g OGTT after a 12-h overnight fast with
measurement of FBG, 2-h plasma glucose (2hPG), and
hemoglobin A1c (HbA1c).
Preparation of recombinant PSP/reg
Human recombinant PSP/reg was expressed in the yeast
pichia pastoris and purified from medium supernatants as
described elsewhere [19]. Briefly, the coding region of PSP/
reg was cloned into a transfer vector containing the signal
sequence of the yeasta-mating factor to drive the protein into
the secretory pathway. A sterile filtered stock solution was
stored at -20 C and protected from light [20].
PSP/reg enzyme-linked immunosorbent assay
The enzyme-linked immunosorbent assay (ELISA) to
quantify human PSP/reg was performed using anti-sera
from rabbits and guinea pigs immunized with recombinant
human PSP/reg protein as previously described [10, 15].
Serum was prepared by centrifugation, and the IgG were
purified by affinity chromatography on protein A columns.
Subsequently, a sandwich ELISA was designed on 96-well
ELISA plates. Antibody of the first species (guinea pig)
was coated to the bottom, blocked with BSA, and aliquots
of serum were then incubated for 2 h. After washing,
antibodies of the other species (rabbit) were incubated.
Finally, a phosphatase-coupled anti-rabbit IgG was used
[21]. The reaction of the phosphatase with a substrate was
determined on a multiplate reader (Dynatech), and sub-
jects’ serum PSP/reg levels were compared with standard
amounts of recombinant human PSP/reg protein.
Statistical analyses
Data are presented as median (interquartile range [IQR]). The
statistical analyses were conducted using a SPSS 17.0 soft-
ware. Correlations of PSP/reg and clinical parameters were
performed using Spearman’s rank correlation coefficient.
Differences between groups were determined by Nemenyi
test. Area under the curve (AUC) values were presented with
95 %confidence intervals (95 %CI). Cut-offswere identified
by Youden’s index. Sensitivity and specificity were used to
calculate likelihood ratios. Correlations and differences were
defined as significant at p\ 0.05.
Results
Participants and baseline characteristics
1121 subjects (479 males, 642 females; age range
23–80 years) participated in the study. The baseline subject
characteristics of the six enrolled populations are summa-
rized in Table 1. These groups were age-matched except
control. The control group in this study was younger than
all the other groups. Young control individuals were cho-
sen to rule out the coincidence with other chronic disease
that may interfere with the levels of PSP/reg. Furthermore,
an analysis of 117 healthy volunteers showed no correla-
tion of PSP/reg with age (R2 = 0.002809).
Elevated PSP/reg levels were detected in T2DM
Wemeasured fasting serumPSP/reg levels in the subjectswith
T2DM at different clinical phases using a newly developed
ELISA assay. PSP/reg levels were elevated in high-risk group
patients as compared to healthy controls (18.7 ng/ml
[15.0–26.4] versus 16.4 ng/ml [13.9–20.8)], p = 0.014). We
also found that PSP/reg levels were significantly higher in the
IGR (18.5 ng/ml [13.7–26.3] versus 16.4 ng/ml [13.9–20.8],
p\ 0.05) and newly diagnosed group (21.0 ng/ml
[14.8–29.4] versus 16.4 ng/ml [13.9–20.8], p\ 0.001). Fur-
thermore, PSP/reg levels were clearly elevated in long-term
858 Endocrine (2015) 48:856–862
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patients with T2DM (without complications: 26.4 ng/ml
[17.4–38.2] versus 16.4 ng/ml [13.9–20.8], p\ 0.001; with
complications: 32.1 ng/ml [22.1–55.5] versus 16.4 ng/ml
[13.9–20.8], p\ 0.001) (Fig. 1).
PSP/reg levels increase with the duration of T2DM
A significant correlation between PSP/reg level and dura-
tion of T2DM (Spearman’s rank correlation coefficient
0.319, p\ 0.001, Fig. 2a) was noted. A correlation
between PSP/reg and HbA1c in all the participants
(Spearman’s rank correlation coefficient 0.188, p\ 0.001
Fig. 2b) was also found. Meanwhile, FBG and 2hPG cor-
related positively with PSP/reg levels. A correlation
between PSP/reg and pulse pressure (systolic pressure-
diastolic pressure) (Spearman’s rank correlation coefficient
0.130, p\ 0.001) and smoking (Spearman’s rank correla-
tion coefficient 0.10, p\ 0.001) were also found. How-
ever, there was no association between PSP/reg and age,
gender, and BMI.
Relationship between PSP/reg and T2DM progression
We set out to assess the predictive value of PSP/reg in
T2DM by receiver operating characteristic (ROC) analysis.
The AUC of PSP/reg for presence of diabetes-onset and
diabetes with chronic complications was 0.640 and 0.754
(95 %CI:0.605–0.674 and 0.694–0.813), respectively. We
identified a PSP/reg cut-off of 22 ng/ml in the nondiabetes
group. Subjects with high PSP/reg (C 22 ng/ml) were more
likely to experience diabetes in future than those with low
PSP/reg levels (\ 22 ng/ml), (Fig. 3a). The sensitivity was
54 % and specificity was 65 % (positive likelihood ratio:
1.54, negative likelihood ratio: 0.70). On the contrary, a
PSP/reg threshold of 27 ng/ml in subjects with T2DM was
the most significant parameter for the presence of chronic
complications of diabetes (Fig. 3b). The sensitivity and
specificity were 65 and 74 % (positive likelihood ratio: 2.5,
negative likelihood ratio: 0.47) respectively.
Discussion
The present study analyzed PSP/reg levels in patients with
different stages of T2DM. We revealed three interesting
new findings. First, patients with diabetes have signifi-
cantly elevated PSP/reg levels, and it is worth noting that
this trend is already observed in the high-risk groups.
Secondly, there is a positive correlation between PSP/reg
Table 1 Clinical characteristics of subjects
Subject group HC HRG IGR Onset LD without C LD with C
Number of subjects 117 254 342 213 116 79
Age (yrs) 28.0 (25.0–33.0) 61.0 (56.0–68.0) 62.0 (56.0–69.3) 62.0 (57.0-69.0) 63.0 (59.0–69.8) 68.0 (57.0–75.0)
Gender male (%) 68 (58.1) 86 (33.9) 114 (33.3) 101 (47.4) 65 (56.0) 45 (57.0)
BMI (kg/m2) 21.7 (19.6–23.9) 24.1 (21.9–25.8) 24.7 (22.9–27.1) 25.3 (23.5–27.5) 23.8 (21.8–25.6) 23.9 (22.0–25.8)
Family history, yes (%) 21 (17.9) 36 (14.2) 64 (18.7) 32 (15.0) 40 (34.5) 28 (35.4)
Smoking, yes (%) 26 (22.2) 46 (18.1) 45 (13.2) 51 (24.1) 29 (25.0) 7 (8.9)
Fasting plasma glucose
(mmol/l)
4.7 (4.5–5.0) 4.9 (4.6–5.3) 5.8 (5.4–6.2) 7.2 (6.4-8.2) 6.0 (5.2–7.5) 7.2 (5.8–9.5)
2-h plasma glucose
(mmol/l)
5.0 (4.8–5.6) 6.1 (5.2–6.7) 7.9 (6.4–9.0) 13.2 (11.6–15.8) 10.2 (8.2–12.6) 10.7 (8.8–13.2)
HbA1c (%) 5.2 (5.1–5.5) 5.7 (5.5–5.9) 6.0 (5.8–6.3) 7.0 (6.5–7.8) 7.1 (6.3–8.3) 8.7 (7.5–10.5)
Clinical characteristics of different groups of subjects, HC Healthy Control, HRG High-Risk Group, IGR Impaired Glucose Regulation, LD
without C Long-term Diabetes Patients without Complications, LD with C Long-term Diabetes Patients with Complications
Data are given as median (IQR)
Fig. 1 Serum levels of PSP/reg in different groups of the study
population. Median PSP/reg serum levels differed significantly in
patients of high-risk (p\ 0.05), impaired glucose regulation
(p\ 0.05), incipient diabetic (p\ 0.001), long-term diabetes without
complications (p\ 0.001), long-term diabetes with complications
(p\ 0.001) as compared to healthy controls. *p\ 0.05, **p\ 0.001.
Ctrl Healthy Control, HRG High-Risk Group, IGR Impaired Glucose
Regulation, LD without C Long-term Diabetes Patients without
Complications, LD with C Long-term Diabetes Patients with
Complications
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levels and the duration of diabetes, which was identified by
a time dependent increase of PSP/reg levels in subjects
with diabetes. Thirdly, PSP/reg level might reflect chronic
complications of diabetes, and may potentially stratify
patient’s outcomes.
Under normal situations, the most predominant origin of
PSP/reg is pancreatic acinar cells, while other tissues,
intestines and islets for instance, appear to produce PSP/reg
predominantly under pathologic conditions [22–25]. Ini-
tially, PSP/reg was suggested as a sensitive marker of
pancreatic injuries, however, other conditions might acti-
vate the secretion of PSP/reg [26, 27]. Recent data revealed
that PSP/reg could discriminate patients with infection,
infection with sepsis and no infection, which might be a
superior marker for posttraumatic complications [14].
Recent studies reported significantly elevated PSP/reg
levels in blood of patients with sepsis [11], VAP [12],
COPD exacerbation [13] and peritonitis [21].
In diabetes, islets are infiltrated by inflammatory cells.
To counteract such attacks, high levels of PSP/reg were
secreted to boost islet cell proliferation [7, 10, 28], as
strong PSP/reg immunoreactivity in peri-vascular and peri-
insular areas were observed [23]. Recent study in insuli-
noma cell lines and mouse models by Bonner et al. pro-
vided biological evidence that b-cells undergoing apoptosis
induce the PSP/reg expression in surviving neighbor b-
cells [15]. A following study by Bacon et al. [16] revealed
that PSP/reg levels are prominently elevated in human
subjects with HNF1A-MODY and TIDM, suggesting a role
for pancreatic injury and b-cells apoptosis as a source for
elevated PSP/reg serum levels. Our findings provided new
evidence that PSP/reg levels were significantly higher in
T2DM patients, especially in patients with chronic com-
plications. The role of inflammation in the pathogenesis of
T2DM and associated complications has been well estab-
lished [29], and PSP/reg was a protein mainly reflect the
progress of inflammation [11–13, 21]. These results further
confirmed that PSP/reg levels show close associations with
diabetes and imply that PSP/reg might be a promising
sensitive marker of diabetes in future. Interestingly, no
statistical differences were found among the high-risk, IGR
and newly diagnosed diabetes patients. It might indicate
Fig. 2 a/b Correlation analysis
of PSP/reg in all subjects.
a Correlation of PSP/reg with
duration of type 2 diabetes
(Spearman r = 0.319,
p\ 0.001). b Correlation of
PSP/reg with HbA1c (Spearman
r = 0.188, p\ 0.001). Lines
represent the trend calculated by
linear regression
Fig. 3 a/b ROC curve analysis: PSP/reg predicts the incidence of
type 2 diabetes (a), and of type 2 diabetes chronic complications (b).
Circles highlight the most accurate cut-offs. Using the 22 ng/mL cut-
off reveals a sensitivity of 54 % and a specificity of 65 % to predict
the incidence of type 2 diabetes (a). 27 ng/mL among patients with
type 2 diabetes was the best threshold to predict the incidence of type
2 diabetes chronic complications (sensitivity: 65 %, specificity: 74 %,
b)
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that diabetes progression might remain at a stable level
during those periods. As a result, this may provide a stra-
tegic period to intervene and hence postpone or even pre-
vent the onset of T2DM.
In our results, circulating PSP/reg values correlate with
diabetes duration which implies that there is a positive cor-
relation between PSP/reg levels and the course of diabetes.
This was identified by a time dependent increase of PSP/reg
levels in subjects with T2DM. Hence, diabetes duration
might be an important risk factor for its complications. We
also found a correlation between PSP/reg levels and HbA1c,
FBG and 2hPGwhich indicates that the elevation of PSP/reg
levels might play an important role in the development of
abnormal glucose tolerance. This observation is in agree-
ment with recent data indicating that increased extracellular
glucose concentrations potentiated PSP/reg gene expression,
which may represent an important physiological feedback
loop for the regulation of b-cell mass [15]. Moreover, cor-
relation between PSP/reg and smokingwas observed as well.
Cigarette smoking induces an inflammatory reaction in the
lung and is a major risk factor for a number of lung diseases
such as COPD. It leads to elevation of soluble markers of
systemic inflammation in circulation [30, 31]. PSP/reg is a
protein mainly reflecting infectious conditions and organ
failure. Therefore, the inflammation in the air spaces of
smokers might lead to elevated PSP/reg level in blood of
smokers. Another correlation between pulse pressure (PP)
and PSP/regwas also found. PP is useful in predicting risk for
atherosclerotic diseases, which are inflammatory in nature
[32, 33]. Thus, this might explain the correlation between
PSP/reg and pulse pressure and its relevance may be
explored in further studies.
For future risk assessment, we calculated the AUC of
PSP/reg for presence of diabetes-onset and diabetes with
chronic complications which were 0.640 and 0.754
(95 %CI:0.605–0.674 and 0.694–0.813), respectively. In the
process of this analysis, we identified two cut-off values, and
found a PSP/reg cut-off of 22 ng/ml in the nondiabetes group
as the most valuable threshold for indicating incidence. On
the contrary, a PSP/reg threshold of 27 ng/ml in subjects of
T2DM was the most significant parameter associated with
the occurrence of diabetes chronic complications. Both cut-
offs are characterized by a high specificity. While these cut-
offs have a high positive likelihood ratio, they have a low
negative likelihood ratio. Thus, negative results (nondiabe-
tes:\22 ng/ml, T2DM:\27 ng/ml) need to be explained
cautiously.
The main strength of this multi-center study is the large
number of T2DM subjects and the grouping according to
the different stages of T2DM. However, this study also has
a few limitations. First, these new findings need to be
considered hypothesis-generating due to their observational
nature. Hence, the exact performance of PSP/reg in the
developing progress of T2DM remains unclear. Although
the study was performed in several centers, external vali-
dation of our results is essential. Therefore, PSP/reg mea-
surements cannot yet be recommended. Second, owing to
its observational characteristic, this hypothesis requires a
randomized, controlled trial to definitively determine the
role of PSP/reg in patients with T2DM. Finally, the exact
origin of elevated PSP/reg in T2DM patients is unknown.
Pancreatic acinar cells are considered as the most important
source of PSP/reg, while other releasing mechanisms and
origins are also possible, but require further research.
Our preliminary data suggest that PSP/reg could be of
clinical use in the stratification of T2DM patients, and may
help to detect patients at high risk of T2DM and identify
chronic complications of diabetes. Thus, PSP/reg might
serve as a potential biomarker in T2DM.
Conclusion
PSP/reg is significantly up-regulated in T2DM patients,
and the PSP/reg level is related to the duration of diabetes.
Therefore, PSP/reg might be useful as a predictor of T2DM
and disease progression. Future trials are required to reas-
sess performance and evaluate the impact of PSP/reg
measurements.
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